Pyrimidinoceptor Potentiation of Macrophage PGE(2) Release Involved in the Induction of Nitric Oxide Synthase
Overview
Affiliations
We have previously demonstrated that Ca(2+)/calmodulin-dependent protein kinase (CaMK) mediates pyrimidinoceptor potentiation of LPS-elicited inducible nitric oxide synthase (iNOS) induction in murine J774 macrophages. In the present paper, we have explored the role of cyclo-oxygenase (COX)-dependent prostaglandin E(2) (PGE(2)) formation in this event. In J774 macrophages predominantly expressing P2Y(6) receptors, the simultaneous addition of UTP and lipopolysaccharide (LPS) resulted in potentiated increase in PGE(2) release. UTP-induced increased PGE(2) release was demonstrated by a concomitant increase in COX-2 protein expression, and was decreased by inhibitors specific for phosphatidylinositide-phospholipase C (PI-PLC), CaMK, protein kinase C (PKC), nuclear factor-kappa B (NF-kappaB) or COX-2. NS-398 (a selective COX-2 inhibitor) reduced LPS plus UTP-elicited iNOS induction and nitrite accumulation, supporting for the positive regulation of iNOS gene expression by endogenous PGE(2). Moreover, the cyclic AMP/PKA-dependent up-regulation of iNOS expression mediated by PGE(2) was drawn from the inhibitory effects of 2',5'-dideoxyadenosine, KT5720 and H-89. Exogenous PGE(2) induced NF-kappaB activation and potentiated nitrite accumulation in response to LPS. In addition to COX-2 induction, arachidonic acid (AA) release and steady-state mRNA levels of type V secretory phospholipase A(2) (sPLA(2)) and Ca(2+)-independent PLA(2) (iPLA(2)) were also increased in the presence of LPS and UTP; the LPS-induced increase in iPLA(2) activity was also potentiated by UTP. Taken together, we conclude that UTP-mediated COX-2 and iPLA(2) potentiation and PGE(2) formation contribute to the iNOS induction, and that CaMK activation is the primary step in the UTP enhancement of COX-2 induction.
Crosstalk between P2Y receptors and cyclooxygenase activity in inflammation and tissue repair.
Povo-Retana A, Sanchez-Garcia S, Alvarez-Lucena C, Landauro-Vera R, Prieto P, Delgado C Purinergic Signal. 2023; 20(2):145-155.
PMID: 37052777 PMC: 10997571. DOI: 10.1007/s11302-023-09938-x.
Prostaglandin E Impairs P2Y/P2Y Receptor Signaling in Cerebellar Astrocytes via EP3 Receptors.
Paniagua-Herranz L, Gil-Redondo J, Queipo M, Gonzalez-Ramos S, Bosca L, Perez-Sen R Front Pharmacol. 2018; 8:937.
PMID: 29311938 PMC: 5743739. DOI: 10.3389/fphar.2017.00937.
A critical look at the function of the P2Y11 receptor.
Dreisig K, Kornum B Purinergic Signal. 2016; 12(3):427-37.
PMID: 27246167 PMC: 5023629. DOI: 10.1007/s11302-016-9514-7.
Purinergic signalling and immune cells.
Burnstock G, Boeynaems J Purinergic Signal. 2014; 10(4):529-64.
PMID: 25352330 PMC: 4272370. DOI: 10.1007/s11302-014-9427-2.
NS-398 reverses hypotension in endotoxemic rats: contribution of eicosanoids, NO, and peroxynitrite.
Tunctan B, Sari A, Kacan M, Unsal D, Buharalioglu C, Sahan-Firat S Prostaglandins Other Lipid Mediat. 2012; 104-105:93-108.
PMID: 22975359 PMC: 3774147. DOI: 10.1016/j.prostaglandins.2012.08.007.